PCI vs CC Score in Peritoneal Metastases

1. The Core Distinction

The Peritoneal Cancer Index (PCI) and Completeness of Cytoreduction (CC) score are often documented together in CRS-HIPEC practice, but they answer different questions.

This distinction helps prevent a common documentation problem. Saying "the patient has a high PCI" does not describe whether the operation achieved visible clearance. Saying "CC-0" does not describe how extensive the original disease was, how difficult the cytoreduction was, or whether the small bowel was heavily involved.

2. PCI vs CC Score Table

3. How The Peritoneal Cancer Index Works

PCI divides the abdomen and pelvis into 13 regions: 9 abdominopelvic regions and 4 small-bowel regions. Each region receives a lesion size (LS) score from 0 to 3 based on the largest visible implant in that region.

The maximum PCI is 39. Higher scores generally indicate greater tumor burden and may reduce the likelihood of complete cytoreduction, especially in colorectal peritoneal metastases. However, exact cutoffs vary by histology, center experience, treatment intent, and whether disease involves critical small-bowel surfaces.

4. How Completeness Of Cytoreduction Score Works

The CC score is assigned after cytoreductive surgery. It describes the size of residual visible tumor, not the initial extent of disease.

CC-0 and CC-1 are often grouped as "complete" cytoreduction in CRS-HIPEC studies, but clinicians should still record the exact category. CC-1 is not the same operative finding as CC-0, and the prognostic meaning can differ by disease type and intraperitoneal regimen.

5. Practical CRS-HIPEC Workflow

1. Pre-referral review: confirm histology, systemic disease status, performance status, nutrition, prior abdominal surgery, and whether the patient may tolerate cytoreduction.
2. Radiology and laparoscopy planning: estimate disease distribution, but recognize that CT often underestimates small implants and small-bowel mesenteric disease.
3. Calculate PCI: use the PCI workflow for a transparent regional total, small-bowel burden flag, and CRS-HIPEC interpretation prompts.
4. Discuss resectability: high PCI, extensive small-bowel involvement, poor biology, or extra-peritoneal disease may shift the plan toward systemic therapy, reassessment, or palliation.
5. Document CC score after surgery: record CC-0, CC-1, CC-2, or CC-3 in the operative note and tumor board summary.
6. Integrate additional prognostic context: consider related tools such as Fong Clinical Risk Score, Glasgow Prognostic Score, and mGPS where clinically appropriate.

For disease-context navigation, see the colorectal cancer calculator hub and the colorectal guideline hub.

6. Interpretation Pitfalls

• Using PCI as a universal cutoff: PCI thresholds are not interchangeable across colorectal, appendiceal, gastric, ovarian, and mesothelioma contexts.
• Missing small-bowel disease: a moderate total PCI with critical small-bowel or mesenteric involvement may be less resectable than a higher score in more favorable locations.
• Equating radiologic PCI with surgical PCI: imaging estimates are useful but may not match laparoscopic or open operative findings.
• Reporting "complete cytoreduction" without the exact CC category: CC-0 and CC-1 should be distinguished when available.
• Ignoring postoperative biology: CC score is an operative endpoint; recurrence risk still depends on histology, grade, nodal disease, systemic therapy response, and molecular features.

7. Frequently Asked Questions